Treatment with GLP-1 RAs in Romanian patients with T2D is associated with a sustainably improved cardiovascular–kidney–metabolic risk profile, ameliorated glycemic control, reduced weight, lower insulin resistance, and slower kidney disease progression. This evidence concerns the gene GLP1R and kidney disorder.